The available interferons are divided into regular and Peg (i.e., long-acting). Peg interferon is more effective than regular interferon and should be chosen as much as possible. Interferon treatment regimens must emphasize individualization, taking into account the patient’s age, gender, degree of liver inflammation, hepatitis B virus genotype and viral level, and the degree of viral decline during treatment to determine the dose and duration of treatment. Interferon has both antiviral and immunomodulatory effects and can increase the rate of hepatitis B virus e antigen and surface antigen transitions with a low relapse rate after discontinuation of the drug. For first-time patients, interferon antiviral therapy is appropriate in the following cases: 1. relatively young patients, patients who plan to have children within 2-3 years, and patients who wish to complete treatment in a relatively short period of time. 2, the first time to receive antiviral therapy patients, if the ALT level ≥ 2 times the upper limit of normal value, but ≤ 1 0 times the upper limit of normal value (note the exclusion of drugs, alcohol and other factors caused by the ALT elevation); total bilirubin level ≤ 2 times the upper limit of normal value, suitable for interferon therapy. 3, the short duration of the disease, non-mother-to-child transmission is more suitable for interferon treatment. 4, no schizophrenia, thyroid disease, heart disease, epilepsy, autoimmune disease, severe neurasthenia, depression and other underlying diseases. The HBV DNA level, HBsAg level before treatment and the reduction in the course of treatment (12 weeks, 24 weeks) have a good predictive effect on the efficacy, and the overall treatment efficiency is about 30%. What should I do if I have an adverse reaction to interferon? Although interferon treatment has more side effects, it is generally safe. A few serious adverse reactions can be detected through regular follow-up, and timely adjustment of interferon dose and additional targeted measures can effectively avoid life-threatening situations and ensure the completion of treatment as planned, so as to achieve the expected results. Therefore, before treatment, doctors and patients should fully communicate and discuss the current disease status, the necessity of carrying out treatment, the treatment options available, the efficacy of interferon treatment, possible problems and solutions during treatment, the importance of regular follow-up, etc., and reach a consensus before starting treatment to improve patient compliance and try to ensure that treatment and follow-up are carried out according to the scheduled plan to improve the efficacy.